Skip to content
Fredrik Swartling

Image -

Fredrik Swartling

Fredrik Swartling, docent vid institutionen för immunologi, genetik och patologi, Uppsala universitet Fredrik Swartling, Researcher at Department of Immunology, Genetics and Pathology, Uppsala University
Maria Swartling
License:
Media Use
The content may be downloaded by journalists, bloggers, columnists, creators of public opinion, etc. It can be used and shared in different media channels to convey, narrate, and comment on your press releases, posts, or information, provided that the content is unmodified. The author or creator shall be attributed to the extent and in the manner required by good practice (this means, for example, that photographers should be attributed).
By:
Maria Swartling
File format:
.jpg
Size:
2382 x 2625, 651 KB
Download

Topics

Contacts

Related content

  • ​Epilepsy drug inhibits brain tumour development

    Medication prescribed for a certain type of epilepsy may offer a new method for treating malignant infantile brain tumours. A specific mTOR inhibitor has the ability to cross the blood–brain barrier to both reach and attack the tumour at source. This has been demonstrated by researchers from Uppsala University, in collaboration with US and UK colleagues, and is published in Cell Stem Cell.

  • ​Läkemedel mot epilepsi hämmar tumörutveckling i hjärnan

    Medicin som används mot en viss typ av epilepsi kan vara ett nytt sätt att behandla elakartade hjärntumörer hos spädbarn. En specifik mTOR-hämmare kan ta sig över blod-hjärnbarriären och både nå och attackera tumören där den finns. Det kan forskare från Uppsala universitet, i samarbete med amerikanska och brittiska kollegor visa och forskningsresultaten publiceras i Cell Stem Cell.